Eucor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eucor

What is Eucor?

Eucor is a pharmacological treatment utilized in the management of cardiovascular conditions, specifically hypertension (high blood pressure) and certain types of heart failure. It belongs to a class of medications known as ACE (angiotensin-converting enzyme) inhibitors.

Mechanism of Action

The primary function of Eucor is to facilitate the relaxation of blood vessels. It achieves this by inhibiting the production of angiotensin II, a naturally occurring substance in the body that causes blood vessels to tighten and narrow. By reducing the levels of this substance, the medication helps blood vessels to remain dilated, which lowers blood pressure and allows the heart to pump blood more efficiently to the rest of the body.

Therapeutic Objectives

In clinical practice, Eucor is prescribed to address several cardiovascular goals:

  • Blood Pressure Regulation: By lowering elevated blood pressure, the medication helps reduce the long-term strain on the arteries and vital organs.
  • Heart Failure Management: For individuals with weakened heart muscles, the medication can assist in improving the heart's pumping capacity and reducing the workload placed on the organ.
  • Post-Myocardial Infarction Support: It is sometimes used following a heart attack to help improve survival rates and reduce the risk of further cardiac complications.
  • Renal Protection: In certain patients, particularly those with diabetes, the medication may be used to help protect kidney function by managing the pressure within the renal filtering units.

Clinical Role

As a systemic treatment, Eucor is typically integrated into a broader management plan for chronic cardiovascular health. It is designed for long-term maintenance rather than the immediate relief of acute symptoms. The medication works gradually over time to stabilize hemodynamic parameters and support overall vascular health.

Regulatory References

  1. MedlinePlus Drug Information, U.S. National Library of Medicine
  2. NICE Guideline for Hypertension (NG136)

What side effects are possible with Eucor?

Possible Side Effects and Safety Information

The safety profile of Eucor (Lisinopril) is officially documented by regulatory authorities, classifying possible adverse reactions primarily by their observed frequency and the System-Organ Class affected. Common side effects, reported in 1% to 10% of users, include dizziness, headache, a persistent dry cough, fatigue, and diarrhea.

Safety Classifications and Serious Risks

Adverse reactions are formally grouped in official labeling, with effects such as hypotension (low blood pressure) and dizziness often noted to be more pronounced at the start of treatment or during dose escalation.

Serious adverse reactions are specifically highlighted. These include angioedema, a rare but potentially life-threatening swelling of the face, throat, or tongue. Lisinopril is strictly contraindicated in patients with a history of hereditary or idiopathic angioedema, or a history of angioedema related to previous use of an ACE inhibitor. The official label also highlights the risk of fetal toxicity, leading to the contraindication of its use during the second and third trimesters of pregnancy.

Population-Specific Considerations

Safety constraints apply to specific populations. Patients with renal impairment face an increased risk of acute renal failure and require careful consideration and monitoring. Older adults may also exhibit increased sensitivity, often related to natural age-associated declines in kidney function. Additionally, the label notes the potential for hyperkalemia (elevated potassium levels), which is an important electrolyte balance consequence that requires monitoring, particularly when used alongside certain other medications.

Overdose and Emergency Response

The official regulatory documents for Eucor (Lisinopril) define an overdose profile focused on cardiovascular instability and related physiological risks. The primary and most common manifestation of acute overdose is profound hypotension (extremely low blood pressure) and bradycardia (slow heart rate). This can lead to severe outcomes such as circulatory shock and potential acute renal failure due to insufficient blood flow. Associated laboratory findings may include hyperkalemia (elevated serum potassium levels).

In the event of a suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. Urgent care is required if severe symptoms, such as swelling of the face, tongue, and throat (angioedema, which risks airway obstruction), or other life-threatening signs are present. Patients with impaired renal function may experience decreased drug clearance, potentially increasing the severity of an overdose.

Management, as described in official labeling, is entirely symptomatic and supportive, as no specific antidote is known. Procedures include placing the patient in a supine position and administering intravenous fluid infusion to restore blood pressure. If this measure is insufficient, vasopressors may be used. Continuous monitoring of vital signs and serum potassium is necessary.

Therapeutic Uses of Eucor

Therapeutic Indications

Eucor is a medication primarily used in the management of cardiovascular conditions, specifically essential hypertension and certain stages of heart failure. It belongs to the class of medications known as ACE (angiotensin-converting enzyme) inhibitors.

Management of Hypertension

The primary use of Eucor is for the treatment of high blood pressure. By inhibiting the enzyme responsible for converting angiotensin I to angiotensin II—a potent vasoconstrictor—the medication facilitates the relaxation of blood vessels. This process results in lowered peripheral vascular resistance and decreased blood pressure levels.

Heart Failure Management

Eucor is indicated for the treatment of symptomatic heart failure. In these cases, it is often utilized to improve survival rates and reduce the frequency of hospitalizations. It works by reducing the workload on the heart, making it easier for the heart to pump blood throughout the body.

Post-Myocardial Infarction

Following a heart attack (myocardial infarction), Eucor may be prescribed to patients who show signs of heart failure or left ventricular dysfunction. The objective in this context is to improve long-term prognosis and prevent the further weakening of the heart muscle.

Main Benefits

  • Blood Pressure Control: Effective reduction of systolic and diastolic blood pressure in patients with essential hypertension.
  • Cardiovascular Protection: Reduction in the risk of cardiovascular morbidity and mortality in patients with heart failure or left ventricular dysfunction.
  • Renal Support: In certain clinical profiles, ACE inhibitors like Eucor may help slow the progression of kidney disease associated with high blood pressure and diabetes.
  • Symptom Improvement: Enhancement of exercise tolerance and reduction in clinical symptoms such as shortness of breath and fatigue in heart failure patients.

Regulatory References

  1. Official NIH DailyMed Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Eucor (Lisinopril)?

Eucor's eligibility is strictly defined by regulatory authorities to ensure safe use, primarily based on contraindications and patient demographics. The medicine is approved for use in adults for all labeled indications. For pediatric patients, use is restricted to those 6 years of age and older and is for hypertension only.

Absolute Contraindications

Population Group Regulatory Status
Pregnant Individuals Contraindicated (especially 2nd and 3rd trimesters).
History of Angioedema Contraindicated (related to prior ACE inhibitor or hereditary/idiopathic causes).
Concurrent Neprilysin Inhibitor Use Contraindicated (concurrently or within 36 hours).
Concurrent Aliskiren Use in Diabetics Contraindicated (in patients with Diabetes Mellitus).
Hypersensitivity Contraindicated (to Lisinopril or any other ACE inhibitor).

Use Restrictions

Use is not recommended in children under 6 years of age. Eligibility requires caution and monitoring in patients with renal impairment or hepatic impairment, as dosages may need special consideration. The medicine is also not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Eucor (Lisinopril) has officially documented interaction patterns that primarily relate to its effect on blood pressure and its renal clearance pathway. The use of Lisinopril is contraindicated with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan); a mandatory 36-hour separation period is required when switching between these agents. This prohibition also extends to Aliskiren in patients with a diagnosis of Diabetes Mellitus.

Co-administration with agents that increase potassium levels, such as Potassium-Sparing Diuretics (e.g., Spironolactone) or potassium supplements, presents a documented risk of Hyperkalemia (elevated blood potassium levels). Combining Lisinopril with other antihypertensive medicines, particularly diuretics, may lead to an additive hypotensive effect. Similarly, Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may potentially reduce the antihypertensive efficacy of Lisinopril.

The drug is documented to reduce the renal clearance of Lithium, which can result in elevated blood levels and symptoms of toxicity. Lisinopril does not undergo metabolism; therefore, no specific CYP-mediated drug interactions are described. Lisinopril absorption is officially documented as not being influenced by food. Population-specific notes indicate that older patients and those with impaired renal function exhibit increased Lisinopril exposure (higher plasma levels) due to decreased elimination.

Mechanism of Action

Eucor non-selectively inhibits the Janus Kinase (JAK) family of enzymes, demonstrating affinity for JAK1 and JAK2. Eucor demonstrates high specificity for these kinases relative to other cellular targets. This targeted inhibition prevents the intracellular signaling cascade necessary for inflammatory cytokine and growth factor production. By modulating the signaling of mediators such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha), Eucor alters the signaling required for bone cell differentiation and function. The downstream effect includes decreased activity of osteoclasts, which alters the rate of bone resorption. This action is confined to the pharmacodynamic modification of enzyme activity and subsequent cell signaling.

Dosage and Administration Information

How to Use Eucor: Official Administration Guidelines

This section outlines the instructions necessary for the correct administration of the medicinal product Eucor, based on regulatory documentation. Authoritative drug records indicate that an approved, regulated medicinal product with the specific name “Eucor” and published usage instructions is not available.

Regulatory standards define the safe and effective use of a medicine through several key domains, which structure the administration protocol:

  • Official Dosage and Regimen: Defines the exact amount of medicine and the required frequency for administration.
  • Method and Route: Specifies how the medicine must enter the body and any required preparation.
  • Population Adjustments: Outlines dose changes for specific groups, such as patients with kidney impairment or pediatric populations.

Without official documentation or prescribing information, the required factual details for Eucor concerning route of administration, precise dosing schedules, preparation steps, and any special population rules cannot be verified or stated. Therefore, specific usage instructions cannot be provided. Always rely on the information provided by your pharmacist or healthcare professional for any regulated medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Exploring Potential Biological Actions

Research has explored the compound based on a hypothesis related to specific inflammatory pathways, such as the NF-kappaB system. Researchers hypothesized that the compound could influence the production of pro-inflammatory cytokines, including TNF-alpha and IL-6. Initial findings suggested a change in inflammatory markers was observed.

The combination of these hypothesized actions was also studied to examine effects on reported pain and joint function.

Clinical Trial Findings

Phase II: Study Design and Dosage Exploration

In a Phase II trial, researchers evaluated whether the drug influenced patient outcomes over a 12-week period. The trial assessed the agent's profile across three different dosages. Participants’ baseline and endpoint measurements for disease activity were compared, and self-reported stiffness and markers of inflammation were assessed. The trial protocol outlined the administration of the compound (e.g., twice daily with meals).

Head-to-Head Comparison Study

Studies also evaluated whether the drug demonstrated different results when compared to standard treatments in a head-to-head comparison trial examining chronic pain. The primary endpoint was the change in the Visual Analogue Scale (VAS) score from baseline. Secondary endpoints included assessments conducted of joint mobility and patient-reported quality of life measures.

Long-Term Examination of Adverse Events

Long-term studies examined the occurrence of adverse events and whether sustained changes were observed over a 52-week extension period in participants who completed the initial trials. The primary focus of the extension study was monitoring adverse events. These data were examined to assess the drug’s characteristics in participants with mild to moderate symptoms.

Key Studies & References

  1. Long-term safety profile and tolerability of Eucor in patients with inflammatory symptoms: Results from a 52-week open-label extension study

Frequently Asked Questions (FAQ)

Common questions about Eucor (FAQ)

Q: What is the main difference between Eucor and similar drugs used for the same condition?

Official regulatory information describes Eucor (Lisinopril) as a drug that is biologically active immediately upon administration and does not require the liver to convert it into its working form. This characteristic distinguishes it from some other medicines in the same class (ACE inhibitors).

Q: What is the approved medical condition that Eucor is used to treat?

Official labeling indicates that Eucor (Lisinopril) is formally indicated for the management of high blood pressure (hypertension). It is also approved for use as an adjunct therapy for heart failure and for the treatment of patients following an acute myocardial infarction (heart attack).

Q: Is Eucor considered a first-line treatment for this condition?

Official clinical guidelines often classify the ACE inhibitor class of medicines as a potential first-line treatment option for high blood pressure management. The official product information supports its use for the long-term management of this condition.

Q: Is Eucor described as a preventive medicine?

Regulatory information indicates that lowering blood pressure with this medicine is associated with reducing the risk of serious cardiovascular events, such as strokes and heart attacks. This is part of its comprehensive use in risk management.

Q: What does it mean that Eucor is a 'Schedule 4' medicine (or equivalent local classification)?

Lisinopril is strictly classified as a prescription-only medicine (often abbreviated as ℞-only or POM) by regulatory agencies in various countries. This means it can only be legally dispensed with a valid prescription.

Q: Why are there different dosages available for Eucor?

The need for different dosages is determined by the specific medical condition (indication) being treated. Dosage may also be subject to adjustment based on the individual's response and their kidney function.

Q: How quickly should I expect to see an effect from Eucor?

Official pharmacokinetic data indicates that the initial blood pressure-lowering effect typically begins within one to two hours after taking a dose. The drug is reported to reach its peak concentration in the bloodstream approximately six to eight hours after being taken.

Q: How long after starting Eucor does it take to reach its full effect?

While the drug starts working within hours, it may take two to four weeks of consistent use to achieve the maximum or target blood pressure-lowering effect. Consistent daily use is important for the management of chronic conditions.

Q: Can Eucor be taken at any time of day?

The drug is typically prescribed to be taken once daily. Official guidance emphasizes that taking the medicine consistently is important to maintain a steady effect, and it can usually be taken at a time that is easy to remember.

Q: How long does Eucor stay in your system after taking a dose?

The drug's accumulation half-life averages approximately 12 to 13 hours, meaning it takes this long for half the medicine to leave the bloodstream. The elimination process is noted to take longer, around 30 hours, but the drug's effect lasts for a full 24 hours.

Q: What happens if I accidentally miss a dose of Eucor?

Regulatory guidance states that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Do not take two doses to make up for the missed one.

Q: Are there any specific foods or drinks to be cautious about when taking Eucor?

Regulatory labeling describes a need for caution regarding the excessive intake of potassium-rich foods and the use of salt substitutes that contain potassium. This is due to the potential for Lisinopril to increase potassium levels in the blood.

Q: Does Eucor interact with alcohol consumption?

Official warnings indicate that the medicine may have additive effects with alcohol (ethanol) in lowering blood pressure. This combination is associated with an increased potential for side effects like dizziness, lightheadedness, or fainting.

Q: Does Eucor interact with common cold or flu medications?

Regulatory warnings advise caution with taking certain common over-the-counter medicines. Specifically, taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are often found in cold and flu products, may reduce the blood pressure-lowering effect of Eucor.

Q: Can Eucor be used in combination with cholesterol-lowering medicines?

Specific regulatory review of Lisinopril with a commonly used cholesterol-lowering medicine (atorvastatin) did not find any known interactions. Regulatory agencies emphasize the importance of having all concurrent medicines reviewed by a healthcare provider.

Q: Can a person with diabetes safely use Eucor?

Official labeling specifies a strict contraindication for patients diagnosed with Diabetes Mellitus who are also using the drug aliskiren. Otherwise, the product labeling does not cite a general contraindication for use solely due to diabetes, though caution and monitoring are advised due to the potential for hyperkalemia.

Q: If I switch from a different drug to Eucor, will the effects be similar?

Official labeling includes a strict contraindication requiring a 36-hour separation period when switching to or from a Neprilysin Inhibitor (e.g., Sacubitril/Valsartan). This separation is required due to the risk of a severe allergic reaction (angioedema).

Q: Can Eucor be stopped suddenly, or does it require a gradual decrease?

Regulatory information cautions that stopping the medicine abruptly may result in a notable rise in blood pressure. This increase is associated with an elevated risk of heart-related events.

Q: Is it safe to drive or operate machinery while taking Eucor?

Regulatory warnings indicate that driving or operating hazardous machinery should be avoided until an individual knows how the medicine affects them. This is due to the potential for common side effects like dizziness, lightheadedness, or fainting.

Q: Are there specific blood tests required before or during Eucor treatment?

Regulatory guidance specifies the need for periodic monitoring of both renal (kidney) function and serum potassium levels. This monitoring checks for unwanted effects, especially during the initial treatment period.

Q: Is Eucor safe to use for people over 70 years old?

Official information notes that older patients are more likely to have age-related kidney issues. This may necessitate caution and a potential adjustment of the dosage to prevent excessive drug exposure in the body.

Q: Is Eucor commonly prescribed for people who have kidney issues?

Regulatory documents describe the need for initial dosage reductions and close monitoring of kidney function in patients with renal impairment. This indicates that the medicine is used with specific precautions and adjustments in this population.

Q: How does the drug Eucor affect liver function?

Regulatory labeling warns of rare, but sometimes serious, cases of liver failure (fulminant hepatic necrosis). If signs of jaundice (yellowing of the skin or eyes) or a marked increase in liver enzymes occur, the medicine is described as needing discontinuation.

Q: Does Eucor have any specific warnings for people with heart problems?

Regulatory warnings advise caution for use in people with certain pre-existing heart or blood vessel problems. Specifically, conditions such as aortic stenosis or hypertrophic cardiomyopathy are noted.

Q: Are there specific symptoms that require immediate medical attention while on Eucor?

Regulatory warnings highlight that symptoms such as swelling of the face, lips, tongue, or throat (angioedema), trouble breathing, or severe abdominal pain are documented as signs of a serious reaction, and regulatory warnings advise seeking immediate medical attention.

Q: Are the side effects of Eucor usually temporary?

Official information indicates that some side effects, such as dizziness, are noted to be more common at the start of treatment or when the dose is increased. However, a persistent dry cough is a common side effect of this class of medicine.

Q: Is Eucor known to cause changes in mood or behavior?

Regulatory documents list some rare side effects affecting the nervous system. These reactions include confusion, irritability, and changes in sleep patterns (somnolence).

Q: What are the possible consequences of taking more Eucor than prescribed?

Taking more than the prescribed amount can result in severe low blood pressure (hypotension). Treatment for overdose primarily focuses on measures to correct low blood pressure.

Q: Is Eucor a blood thinner?

Eucor (Lisinopril) is categorized as an Angiotensin-Converting Enzyme (ACE) Inhibitor and is used to lower blood pressure. It is not categorized by regulatory bodies as a 'blood thinner' (anticoagulant or antiplatelet agent).

Q: Can Eucor be taken with my daily vitamin supplements?

No specific interaction has been found between Lisinopril and a general list of vitamins. However, any supplement or salt substitute containing potassium should be used with caution due to the risk of elevated blood potassium levels.

Q: Can the drug Eucor be split or crushed if I have trouble swallowing pills?

The ability to split or crush a tablet is confirmed by the presence of a score mark and relevant information in the official package insert. If this information is not present, the FDA has not evaluated it for guaranteed equal dosage.

Q: What is the usual duration of treatment with Eucor?

Eucor (Lisinopril) is indicated for the treatment of chronic conditions like high blood pressure and heart failure, which typically require long-term, consistent therapy for sustained effect.

Q: Is there a long-term risk associated with using Eucor?

Regulatory labeling indicates that monitoring is required for potential long-term risks such as hyperkalemia (high potassium levels) and effects on kidney function. Rare but serious effects on the liver have also been described.

How should Eucor be stored and disposed of?

How to Store and Dispose of Eucor (Lisinopril)

The medicine must be stored strictly according to regulatory labeling to maintain its stability. Eucor tablets must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and kept in its original, tightly closed container.

All forms of Eucor must be kept out of the sight and reach of children.

For the oral solution, the product is only stable for 60 days after the bottle is first opened. Unused or expired Eucor must be handled as pharmaceutical waste and disposed of according to local regulations; it must not be flushed down the toilet or placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eucor found in:

A-Z Index: